argenx to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/10/22
12 biotech stocks to consider buying now as prospects for the sector brighten this yearMarket Watch • 02/06/22
argenx Announces VYVGART™ Approval in Japan for the Treatment of Generalized Myasthenia GravisBusiness Wire • 01/20/22
argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia GravisBusiness Wire • 12/17/21
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 10/28/21
argenx Reports Third Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 10/28/21
argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021GlobeNewsWire • 10/21/21
argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular MeetingsGlobeNewsWire • 10/08/21
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia GravisGlobeNewsWire • 08/25/21
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/01/21
argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business UpdateGlobeNewsWire • 07/29/21
argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021GlobeNewsWire • 07/22/21
argenx announces publication of Phase 3 ADAPT trial results of efgartigimod for the treatment of generalized myasthenia gravis in The Lancet NeurologyGlobeNewsWire • 06/16/21